中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
5期
58-60
,共3页
药品不良反应%监测%分析
藥品不良反應%鑑測%分析
약품불량반응%감측%분석
ADR%Monitoring%Analysis
目的:探讨药品引发不良反应(ADR)发生的相关因素。方法对我院2013年1~12月收集的175例ADR报告进行回顾性分析总结。结果175例ADR报告中,性别比为男:女=1∶1.30;年龄方面以>60岁患者发生率最高,共76例(43.43%);静脉输液引发的ADR 共126例(72.00%);口服占38例(29.58%)。涉及药品种类抗感染药物73例(41.74%),抗肿瘤药物21例(19.29%),心血管药物24例(13.71%),中药制剂19例(10.86%)。ADR涉及的系统及器官以皮肤、附件多见,77例(44.00%)。结论女性、老年患者发生ADR的较多,涉及多个系统,与年龄、给药途径、药品种类等关系密切。
目的:探討藥品引髮不良反應(ADR)髮生的相關因素。方法對我院2013年1~12月收集的175例ADR報告進行迴顧性分析總結。結果175例ADR報告中,性彆比為男:女=1∶1.30;年齡方麵以>60歲患者髮生率最高,共76例(43.43%);靜脈輸液引髮的ADR 共126例(72.00%);口服佔38例(29.58%)。涉及藥品種類抗感染藥物73例(41.74%),抗腫瘤藥物21例(19.29%),心血管藥物24例(13.71%),中藥製劑19例(10.86%)。ADR涉及的繫統及器官以皮膚、附件多見,77例(44.00%)。結論女性、老年患者髮生ADR的較多,涉及多箇繫統,與年齡、給藥途徑、藥品種類等關繫密切。
목적:탐토약품인발불량반응(ADR)발생적상관인소。방법대아원2013년1~12월수집적175례ADR보고진행회고성분석총결。결과175례ADR보고중,성별비위남:녀=1∶1.30;년령방면이>60세환자발생솔최고,공76례(43.43%);정맥수액인발적ADR 공126례(72.00%);구복점38례(29.58%)。섭급약품충류항감염약물73례(41.74%),항종류약물21례(19.29%),심혈관약물24례(13.71%),중약제제19례(10.86%)。ADR섭급적계통급기관이피부、부건다견,77례(44.00%)。결론녀성、노년환자발생ADR적교다,섭급다개계통,여년령、급약도경、약품충류등관계밀절。
Objective To study the related factors of occurrence of adverse drug reactions(ADR). Methods To retrospectively analyze the ADR reports in 175 cases which were selected in our hospital from January to December 2013.ResultsOf the 175 ADR reports,proportion of male and female was 1∶1.30,the incidence of the ADR reports of 76 cases(43.43%)in 60 years older were higher,the ADR reports of intravenous administration and oral administration were 126 cases(72.00%)and 38 cases(29.58%).The ADR reports related to drug varieties were anti infective agents in 73 cases(41.74%),antitumor drugs in 21 cases(19.29%),cardiovascular drugs in 24 cases (13.71%),traditional Chinese medicine preparations in 19 cases(10.86%).The ADR reports related to system and organ in skin and accessory with 77 cases(44.00%)were mostly found. Conclusion The ADR which was closely related to multi-system,the age,the route of administration,the drug varieties is commonly occurred in female and elderly patients.